FiercePharma |
PhIII data puts AZ one step closer to severe-asthma showdown with GSK
FiercePharma Last week, the British drugmaker announced that its candidate for severe asthma with eosinophilic inflammation–benralizumab–had nailed its primary endpoint in two Phase III studies, beating out placebo at paring down the annual asthma exacerbation … |
View full post on asthma – Google News